CD27-Armored BCMA CAR T Cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial.
Xu Y, Zhang X, Xin D, Zhang J, Wang L, Fan Y, Chen B, Lei W, Qiu X, Jiang H, Xiao X, Huang L, Yu J, Yang X, Yang W, Zhu J, Qian W.
Xu Y, et al. Among authors: xiao x.
Cancer Immunol Res. 2024 Oct 21. doi: 10.1158/2326-6066.CIR-24-0051. Online ahead of print.
Cancer Immunol Res. 2024.
PMID: 39432745